NASDAQ: ATRAAtara Biotherapeutics Inc Stock
$12.39-0.33 (-2.59%)
Updated Dec 4, 2024
ATRA Price
$12.39
Fair Value Price
N/A
Market Cap
$71.36M
52 Week Low
$6.50
52 Week High
$39.50
P/E
-0.48x
P/B
-0.79x
P/S
0.6x
PEG
N/A
Dividend Yield
N/A
Revenue
$100.44M
Earnings
-$133.16M
Gross Margin
82.7%
Operating Margin
-127.81%
Profit Margin
-132.6%
Debt to Equity
-2.58
Operating Cash Flow
-$95M
Beta
1.64
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ATRA Overview
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ATRA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Value
B
Growth
C
Momentum
D
Sentiment
F
Safety
F
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ATRA
Ranked#214 of 335
Ranked#214 of 335
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $26.49 | A | |
| $7.53 | A | |
| $123.45 | A |
Be the first to know about important ATRA news, forecast changes, insider trades & much more!
ATRA News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ATRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ATRA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ATRA is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
ATRA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more ATRA due diligence checks available for Premium users.
Valuation
ATRA fair value
Fair Value of ATRA stock based on Discounted Cash Flow (DCF)
Price
$12.39
Fair Value
-$2.33
Undervalued by
631.52%
ATRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ATRA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.48x
Industry
-98.09x
Market
28.79x
ATRA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.79x
Industry
5.6x
ATRA's financial health
Profit margin
Revenue
$40.2M
Net Income
-$21.9M
Profit Margin
-54.5%
ATRA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ATRA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$142.7M
Liabilities
$233.2M
Debt to equity
-2.58
ATRA's short-term liabilities ($155.98M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ATRA's short-term assets ($91.86M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ATRA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ATRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.0M
Investing
-$16.7M
Financing
$35.8M
ATRA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ATRA vs Biotech Stocks
Atara Biotherapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.